KIT and mucosal melanoma: In a phase II trial evaluating the efficacy of imatinib in patients with metastatic melanoma [17/24 (71%) patients with mucosal melanoma] harboring activating KIT mutations or amplifications, imatinib provided an overall response rate of 29% and an overall disease control rate of 50%.